450
Participants
Start Date
March 22, 2023
Primary Completion Date
August 28, 2024
Study Completion Date
August 28, 2024
JYNNEOS
JYNNEOS is FDA-approved and licensed as a smallpox and monkeypox vaccine in the United States. JYNNEOS is a live vaccine produced from the strain Modified Vaccinia Ankara-Bavarian Nordic (MVA-BN), an attenuated, non-replicating orthopoxvirus.
UPMC University Center, Pittsburgh
Children's Hospital of Philadelphia, Philadelphia
George Washington University Medical Faculty Associates, Washington D.C.
Duke Vaccine and Trials Unit, Durham
Vanderbilt University Medical Center, Nashville
Children's of Alabama Child Health Research Unit (CHRU), Birmingham
Emory University School of Medicine, Atlanta
University of Maryland, School of Medicine, Center for Vaccine Development and Global Health, Baltimore
NIH Clinical Research Center, Investigational Drug Management and Research Section, Bethesda
Brigham and Women's Hospital, Boston
Saint Louis University Center for Vaccine Development, St Louis
Washington University in St. Louis, St Louis
University of Rochester Medical Center, Rochester
Cincinnati Children's Hospital Medical Center Vaccine Research Center, Cincinnati
University of Texas Medical Branch, Galveston
Baylor College of Medicine, Houston
Kaiser Permanente Washington Health Research Institute, Seattle
Ponce Medical School Foundation Inc., CAIMED Center, Ponce
National Institute of Allergy and Infectious Diseases (NIAID)
NIH